The aim of this study was to investigate the relationship between EPHXI exon 3 Tyr113His and exon 4 His139Arg polymorphisms, predicted microsomal epoxide hydrolase (mEH) activity, and lung cancer development. mEH is a protective enzyme involved in oxidative defences against a number of environmental chemicals and pollutants, but it is also responsible for the xenobiotic activation of carcinogens.
Methods
We investigated the two polymorphisms of the mEH gene (EPHX1) in 58 lung cancer patients and 41 controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results
The exon 3 Tyr113His polymorphism was associated with lung cancer (P <0.001). The frequency of the His113His homozygote genotype in exon 3 was significantly increased in patients compared with controls (P <0.001). In contrast, there was no significant difference in exon 4 polymorphisms between patients and controls. When the exon 3 and 4 polymorphisms were considered together, the combined EPHX1 His113His113/His139His139 genotype (very low predicted enzyme activity) was found to be associated with an increased risk of lung cancer (P = 0.044, OR = 3.063, CI = 0.932–10.069). We observed that patients with T3 + T4 tumors had an approximately 3-fold higher risk of the Tyr113/His113 genotype than patients with T1 + T2 tumors. Lung cancer patients carrying aheterozygote Tyr113/His113 genotype had a 2-fold increased risk of lymph node metastases (P = 0.051).
Conclusion
These findings suggest that the exon 3 Tyr113His and exon 4 His139Arg polymorphisms of EPHXI may be associated with a increased risk of lung cancer and a worse prognosis. Free full text available at www.tumorionline.it
ZusterzeelP.L.M., PetersW.H.M., VisserW., HermsenK.J.M., RoelofsH.M.J., SteegersE.A.P.: A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. J Med Genet, 38: 234–237, 2001.
2.
ZhangJ.H., JinX., LiY., WangR., GuoW., WangN., WenD.G., ChenZ.F., KuangG., WeiL.Z., WangS.J.Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China. World J Gastroenterol, 9: 2654–2657, 2003.
3.
OeschF.: Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica, 3: 305–340, 1973.
WangP., MeijerJ., GuengerichF.P.: Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme. Biochemistry, 21: 5769–5776, 1982.
6.
OmiecinskiC.J., AicherL., HolubkovR., CheckowayH.: Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogentics, 3: 150–158, 1993.
7.
YinL., PuY., LiuT.Y., TungY.H., ChenK.W., LinP.: Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer, 33: 133–141, 2001.
8.
RaakaS., HassettC., OmiecinskiC.J.: Human microsomal epoxide hydrolase: 5‘-flanking region genetic polymorphisms. Carcinogenesis, 19: 387–393, 1998.
9.
HassettC., AicherL., SidhuJ.S., OmiecinskiC.J.: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet, 3: 421–428, 1994.
10.
WuX., GwynK., AmosC.I., MakanN., HongW.K., SpitzM.R.: The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis, 22: 6923–6928, 2001.
11.
GsurA., ZidekT., SchnattingerK., FeikE., HaidingerG., HollausP., Mohn-StaudnerA., ArmbrusterC., MadersbacherS., SchatzlG., TriebK., VutucC., MickscheM.: Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer, 89: 702–706, 2003.
12.
PerssonI., JohanssonI., LouY.C., YueQ.Y., DuanL.S., BertilssonL., Ingelman-SundbergM.: Genetic polymorphism of xenobiotic metabolising enzymes among Chinese lung cancer patients. Int J Cancer, 81: 325–329, 1999.
13.
World Health Organisation. International histological classification of tumours, 3rd ed, Springer Verlag, Berlin-Heidelberg, 1999.
14.
MillerS.A., DykesD.D., PoleskyH.F.: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16: 1215, 1988.
15.
LinY.C., WuD.C., LeeJ.M., HsuH.K., KaoE.L., YangC.H., WuM.T.: The association between microsomal epoxide hydrolase genotypes and esophageal squamous-cell-carcinoma in Taiwan: interaction between areca chewing and smoking. Cancer Lett, 237: 281–288, 2006.
16.
SmithC.A.D., HarrisonD.J.: Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet, 350: 630–633, 1997.
17.
CroceC.M.Oncogenes and cancer. N Engl J Med, 358: 502–511, 2008.
18.
KiyoharaC., YoshimasuK.Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis. Int J Med Sci, 4: 59–71, 2007.
19.
MattsonM.E., PollackE.S., CullenJ.W.: What are the odds that smoking will kill you?Am J Public Health, 77: 425, 1987.
20.
HirvonenA.: Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect, 107: 37–47, 1999.
21.
GonzalezF.J., SamoreM., McQuiddyP., KasperC.B.: Effects of 2-acetylaminofluorene and N-hydroxy-2-acetylaminofluorene on the cellular levels of epoxide hydratase, cytochrome P-450b, and NADPH-cytochrome c (P-450) oxidoreductase messenger ribonucleic acids. J Biol Chem, 257: 11032–11036, 1982.
22.
JerinaD.M.: The 1982 Bernard B. Brodie Award Lecture. Metabolism of aromatic hydrocarbons by the cytochrome P-450 system and epoxide hydrolase. Drug Metab Dispos, 11: 1–4, 1983.
23.
LondonS.J., SmartJ., DalyA.K.: Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer, 28: 147–155, 2000.
24.
To-FiguerasJ., GeneM., Gomez-CatalanJ., PiqueE., BorregoN., CorbellaJ.: Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione-s-transferase P1. Cancer Lett, 173: 155–162, 2001.
25.
BartschH., NairU., RischA., RojasM., WilkmanH., AlexandrovK.: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco related cancers. Cancer Epidemiol Biomarkers Prev, 9: 3–28, 2000.
26.
BenhamouS., ReinikainenM., BouchardyC., DayerP., HirvonenA.: Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res, 58: 5291–5293, 1998.
27.
PastorelliR., GuanciM., CerriA., NegriE., La VecchiaC., FumagalliF., MezettiM., CappelliR., PanigalliT, FanelliR., AiroldiL.: Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a) pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev, 7: 703–709, 1998.
28.
PetruzzelliS., CamusA.M., CarozziL., GhelarducciL., RindiM., MenconiG., AngelettiC.A., AhotupaM., HietanenE., AitioA., SaracciR., BartschH., GiuntiniC.: Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case control study on lung cancer patients. Cancer Res, 48: 4695–4700, 1988.
29.
ZhouW., ThurstonS.W., LiuG., XuL., MillerD.P., WainJ.C., LynchT.J., SuL., ChristianiD.C.: The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev, 10: 461–466, 2001.
30.
HabalovaV., SalagovicJ., KalinaI., StubnaJ.: Combined analysis of polymorphisms in glutathione S-transferase M1 and microsomal epoxide hydrolase in lung cancer patients. Neoplasma, 51: 352–357, 2004.
31.
LinP., WangS.L., WanhH.J., ChenK.W., LeeH.S., TsaiK.J., ChenC.Y., LeeH.: Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Br J Cancer, 82: 852–857, 2000.
32.
TsaiY., McGlynnK.A., HuY., CassidyA.B., ArnoldJ., EngstromP.F., BuetowK.H.: Genetic susceptibility and dietary patterns in lung cancer. Lung Cancer, 41: 269–281, 2003.
33.
KiyoharaC., YoshimasuK., TakayamaK., NakanishiY.: EPHX1 polymorphisms and the risk of lung cancer. A HuGE Review. Epidemiology, 17: 89–99, 2006.
34.
SandfordA.J., ChaganiT., WeirT.D., ConnettJ.E., AnthonisenN.R., ParéP.D.: Susceptibility genes for rapid decline of lung function in the Lung Health Study. Am J Respir Crit Care Med, 163: 469–473, 2001.
35.
RuschV.W., CrowleyJ., GirouxD.J., GoldstrawP., ImJ.G., TsuboiM., TsuchiyaR., VansteenkisteJ.: The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol, 2: 603–612, 2007.
36.
DemirA., AltinS., PehlivanD., DemirM., YakarF., SeyhanE.C., DincerS.I.: The role of GSTM1 gene polymorphisms in lung cancer development in Turkish population. J Carcinogenesis, 7: 13, 2007.
37.
AdaA.O., SuzenH.S., IscanM.: Polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1 in a male Turkish population. Int J Toxicol, 26: 41–46, 2007.
38.
PinarbasiE., PercinF.E., YilmazM., AkgunE., CetinM., ÇetinA.: Association of microsomal epoxide hydrolase gene polymorphism and pre-eclampsia in Turkish women. J Obstet Gynaecol Res, 33: 32–37, 2007.
